Last reviewed · How we verify

Proactive TDM-based dosing of ixekizumab

University Hospital, Ghent · FDA-approved active Small molecule

Proactive TDM-based dosing of ixekizumab is a IL-17A inhibitor; monoclonal antibody Small molecule drug developed by University Hospital, Ghent. It is currently FDA-approved for Psoriasis (plaque psoriasis), Psoriatic arthritis, Ankylosing spondylitis. Also known as: Taltz.

Ixekizumab is an IL-17A inhibitor that blocks interleukin-17A signaling to reduce inflammatory responses in autoimmune conditions.

Ixekizumab is an IL-17A inhibitor that blocks interleukin-17A signaling to reduce inflammatory responses in autoimmune conditions. Used for Psoriasis (plaque psoriasis), Psoriatic arthritis, Ankylosing spondylitis.

At a glance

Generic nameProactive TDM-based dosing of ixekizumab
Also known asTaltz
SponsorUniversity Hospital, Ghent
Drug classIL-17A inhibitor; monoclonal antibody
TargetIL-17A
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By blocking IL-17A, the drug suppresses Th17 cell-mediated inflammation. This entry describes a therapeutic drug management (TDM) approach using proactive therapeutic drug monitoring to optimize ixekizumab dosing based on serum concentrations and clinical response.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Proactive TDM-based dosing of ixekizumab

What is Proactive TDM-based dosing of ixekizumab?

Proactive TDM-based dosing of ixekizumab is a IL-17A inhibitor; monoclonal antibody drug developed by University Hospital, Ghent, indicated for Psoriasis (plaque psoriasis), Psoriatic arthritis, Ankylosing spondylitis.

How does Proactive TDM-based dosing of ixekizumab work?

Ixekizumab is an IL-17A inhibitor that blocks interleukin-17A signaling to reduce inflammatory responses in autoimmune conditions.

What is Proactive TDM-based dosing of ixekizumab used for?

Proactive TDM-based dosing of ixekizumab is indicated for Psoriasis (plaque psoriasis), Psoriatic arthritis, Ankylosing spondylitis, Axial spondyloarthritis.

Who makes Proactive TDM-based dosing of ixekizumab?

Proactive TDM-based dosing of ixekizumab is developed and marketed by University Hospital, Ghent (see full University Hospital, Ghent pipeline at /company/university-hospital-ghent).

Is Proactive TDM-based dosing of ixekizumab also known as anything else?

Proactive TDM-based dosing of ixekizumab is also known as Taltz.

What drug class is Proactive TDM-based dosing of ixekizumab in?

Proactive TDM-based dosing of ixekizumab belongs to the IL-17A inhibitor; monoclonal antibody class. See all IL-17A inhibitor; monoclonal antibody drugs at /class/il-17a-inhibitor-monoclonal-antibody.

What development phase is Proactive TDM-based dosing of ixekizumab in?

Proactive TDM-based dosing of ixekizumab is FDA-approved (marketed).

What are the side effects of Proactive TDM-based dosing of ixekizumab?

Common side effects of Proactive TDM-based dosing of ixekizumab include Injection site reactions, Nasopharyngitis, Upper respiratory tract infections, Candida infections, Inflammatory bowel disease (exacerbation or new onset).

What does Proactive TDM-based dosing of ixekizumab target?

Proactive TDM-based dosing of ixekizumab targets IL-17A and is a IL-17A inhibitor; monoclonal antibody.

Related